National and subnational burden of MDR-TB in China, 1990-2023: Spatio-temporal heterogeneity, long-term trends, and projections.

Authors

Shunxian Zhang, Jinlei Qi, Jinxin Zheng, Yu Qin, Jian Yang, Xiaojie Li, Jichun Wang, Maigeng Zhou, Hui Jiang

Published in

The Journal of infection. Pages 106816. Jul 17, 2026. Epub Jul 17, 2026.

Abstract

Multidrug-resistant Tuberculosis (MDR-TB) remains a major public health threat in China, Geographic heterogeneity and poorly understood epidemiological trends limit precision control and resource optimization.
This study systematically assessed the disease burden of MDR-TB in China and its provinces from 1990 to 2023, using data from the Global Burden of Disease Study (GBD) 2023 database. The analysis includes age-standardized rates (ASR) and absolute case numbers for incidence, prevalence, mortality, disability-adjusted life years (DALYs), years of life lost (YLL), and years lived with disability (YLD). The data spans 31 provinces, autonomous regions, municipalities, and the Special Administrative Regions of Hong Kong and Macao. The Joinpoint regression model was used to analyze trends in disease burden from 1990 to 2023 and calculate the average annual percentage change (AAPC) and annual percentage change (APC). In addition, a Bayesian age-period-cohort (BAPC) model was employed to project the disease burden trends from 2024 to 2050.
In 2023, the age-standardized incidence rate (ASIR) and age-standardized prevalence rate (ASPR) of MDR-TB in China were 1.630 per 100,000 population [95% uncertainty interval (UI): 0.196, 4.967] and 2.740 per 100,000 population (95% UI: 0.340, 8.794), respectively. From 1990 to 2023, ASIR declined significantly [AAPC = -2.859%, 95% confidence interval(CI): -3.487, -2.231], whereas ASPR increased significantly (AAPC = 7.800%, 95% CI: 7.022, 8.578); however, recent trends suggested stabilization, with ASIR plateauing from 2016 to 2023 (AAPC=-0.270%, 95%UI: -1.275, 0.746) and ASPR showing no significant change from 2017 to 2023 (APC = 0.503%, 95% CI: -1.635, 2.687). In 2023, age-standardized mortality rate (ASMR), age-standardized Disability-adjusted life years rate (ASDR), age-standardized Years of Life Lost rate(ASYLLR), and age-standardized Years Lived with Disability rate (ASYLDR) were 0.098 per 100,000 population (95% UI: 0.011, 0.354. AAPC = -6.714%, 95% CI: -7.265, -6.164), 3.718 per 100,000 population (95% UI: 0.466, 13.091. AAPC = -6.633%, 95% CI: -7.130, -6.135), 2.837 per 100,000 population (95% UI: 0.331, 10.333. AAPC = -6.633%, 95% CI: -7.130, -6.135), and 0.881 per 100,000 population (95% UI: 0.118, 2.943. AAPC = -1.614%, 95% CI: -2.366, -0.862), respectively, with significant long-term declines. Xinjiang had the highest ASIR(8.212 per 100,000 population, 95%UI: 1.008, 24.719) and ASPR (12.695 per 100,000 population, 95%UI: 1.513, 39.693). ASIR (AAPC=0.160%, 95% CI: 0.137, 0.183) and ASPR (AAPC=0.086%, 95% CI: 0.073, 0.098) are forecasted to rise from 2024 to 2050.
Persistent MDR-TB challenges in China, including rising prevalence and spatial heterogeneity, demand a sustainable model combining policy, AI diagnostics, and community engagement.

PMID:
42468851
Bibliographic data and abstract were imported from PubMed on 18 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.